49美元“司美格鲁肽减重药”美国开卖，诺和诺德股价创5年新低

Core Viewpoint - Hims has launched a low-priced oral version of the weight loss drug semaglutide at $49, impacting the stock prices of major competitors Novo Nordisk and Eli Lilly, which saw declines of 8% and 7% respectively [1][2]. Group 1: Market Impact - Novo Nordisk's stock has dropped nearly 27% over the past five trading days, with a market capitalization now below $150 billion, following pressure on semaglutide sales [1]. - Hims aims to capture market share by offering its version of semaglutide at a price $100 lower than Novo Nordisk's, leveraging the significant demand for weight loss drugs [2]. Group 2: Legal and Regulatory Context - Hims' sale of the generic drug operates in a legal "gray area," as the FDA has not yet taken action to stop such sales despite previous warnings [2][3]. - Novo Nordisk has announced plans to sue Hims, claiming that Hims' actions pose significant risks to patient safety and violate intellectual property rights [2]. Group 3: Industry Dynamics - The market for compounded generic drugs is growing in the U.S., targeting price-sensitive patients, but these drugs lack FDA approval and clinical validation [3]. - FDA officials have indicated that they will take swift action against companies selling "illegal generics" that claim similarity to FDA-approved products [3].